Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FISION CorpFSSN · Entity 131111 | Director | May 31, 2021 | December 28, 2021 |
| Newton Golf Company, Inc.NWTG · Entity 8169 | Director | January 30, 2026 | February 04, 2026 |
| PROFICIENT ALPHA ACQUISITION CORPPAAC · Entity 148637 | Director | May 29, 2019 | May 29, 2019 |
| SPAR Group, Inc.SGRP · Entity 7681 | Director | September 29, 2026 | October 02, 2026 |
| Stewards, Inc.SWRD · Entity 5257 | Director | September 09, 2026 | September 21, 2026 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | March 24, 2026 | March 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FISION Corp
Report date May 31, 2021 · Filed December 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,500,984 |
Ending reported balance
After 2021-11-30 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-05-31 · Grant · Acquired 396,825 · Balance 9,406,559 F1: Independent Director Compensation Row 2 · 2021-08-31 · Grant · Acquired 592,417 · Balance 9,998,976 F1: Independent Director Compensation Row 3 · 2021-11-30 · Grant · Acquired 502,008 · Balance 10,500,984 F1: Independent Director Compensation |
Filing footnotes · ownership attribution and instrument terms
F1: Independent Director Compensation
Newton Golf Company, Inc.
Report date January 30, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,549 |
Reported balance
After 2026-01-30 transaction · row 1
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 18,549 · Balance 18,549 F1: The restricted stock units will vest in full on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest in full on the one year anniversary of the grant date.
PROFICIENT ALPHA ACQUISITION CORP
Report date May 29, 2019 · Filed May 29, 2019
This filing explicitly reported no securities owned.
SPAR Group, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,000 |
Reported balance
After 2026-09-29 transaction · row 1
1 source rowRow 1 · 2026-09-29 · Grant · Acquired 110,000 · Balance 110,000 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the company's common stock upon vesting. The RSUs will vest on September 29, 2027, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the company's common stock upon vesting. The RSUs will vest on September 29, 2027, subject to continued service.
Stewards, Inc.
Report date September 09, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2026-09-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F2: The reporting person beneficially owns no shares of the issuer's common stock as of the Date of Event. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Represents 45,000 restricted stock units granted on May 8, 2026 under the issuer's 2024 Equity Incentive Plan. The units cliff-vest 100% on May 8, 2027, subject to continued service as a director. Each unit represents the right to receive one share of common stock upon settlement. The units have no expiration date other than forfeiture if the vesting conditions are not met. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 45,000 restricted stock units granted on May 8, 2026 under the issuer's 2024 Equity Incentive Plan. The units cliff-vest 100% on May 8, 2027, subject to continued service as a director. Each unit represents the right to receive one share of common stock upon settlement. The units have no expiration date other than forfeiture if the vesting conditions are not met.
F2: The reporting person beneficially owns no shares of the issuer's common stock as of the Date of Event.
ZEVRA THERAPEUTICS, INC.
Report date March 24, 2026 · Filed March 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,400 |
Ending reported balance
After 2026-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-24 · Exercise / conversion · Acquired 39,200 · Balance 84,200 Row 2 · 2026-03-24 · Exercise / conversion · Acquired 39,200 · Balance 123,400 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2033-05-02 | Direct | 19,600 |
Reported balance
After 2026-03-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-24 · Exercise / conversion · Disposed 39,200 · Balance 19,600 F1: The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2034-05-12 | Direct | 0 |
Reported balance
After 2026-03-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-24 · Exercise / conversion · Disposed 39,200 · Balance 0 F2: The shares underlying this option, which was granted on May 13, 2024, were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director.
F2: The shares underlying this option, which was granted on May 13, 2024, were fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 04:57 UTC | SPAR Group, Inc. SGRP · Entity 7681 | GrantCommon Stock | 110,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-031787 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 F1 · price: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the company's common stock upon vesting. The RSUs will vest on September 29, 2027, subject to continued service. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 12:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001612084-26-000002 · wk-form4_1774528025.xml · derivative · entry 4 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,200 shares Expires 2034-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option, which was granted on May 13, 2024, were fully vested. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 12:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001612084-26-000002 · wk-form4_1774528025.xml · derivative · entry 3 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,600 Underlying: Common Stock · 39,200 shares Expires 2033-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 12:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 39,200 | $4.89 | $191,688.00 |
DisclosureSEC source: 0001612084-26-000002 · wk-form4_1774528025.xml · nonDerivative · entry 2 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 12:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 39,200 | $4.97 | $194,824.00 |
DisclosureSEC source: 0001612084-26-000002 · wk-form4_1774528025.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Feb 4, 2026 01:58 UTC | Newton Golf Company, Inc. NWTG · Entity 8169 | GrantCommon Stock | 18,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-004958 · ownership.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,549 F1 · shares: The restricted stock units will vest in full on the one year anniversary of the grant date. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 20:38 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 5,000 | $9.17 | $45,825.00 |
DisclosureSEC source: 0001437749-25-027456 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Read SEC document |
| May 29, 2025 Filed May 31, 2025 01:38 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-019045 · rdgdoc.xml · derivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:06 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 10,000 | $7.96 | $79,624.00 |
DisclosureSEC source: 0001437749-25-008738 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.91 to $8.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 15, 2024 20:10 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 10,000 | $5.87 | $58,661.00 |
DisclosureSEC source: 0001437749-24-022734 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.81 to $5.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2024 Filed May 16, 2024 01:31 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001437749-24-017190 · rdgdoc.xml · derivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2034-05-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:40 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 10,000 | $5.13 | $51,333.00 |
DisclosureSEC source: 0001437749-23-025313 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.12 to $5.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 2,451 | $5.05 | $12,377.55 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 6 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 100 | $5.05 | $504.50 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 5 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,549 Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 4,759 | $5.04 | $23,985.36 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 4 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,449 Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,000 | $5.04 | $5,039.90 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 3 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,690 Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 300 | $5.04 | $1,511.73 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 2 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,690 Read SEC document |
| May 18, 2023 Filed May 19, 2023 21:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,390 | $5.04 | $6,998.65 |
DisclosureSEC source: 0001437749-23-015335 · rdgdoc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,390 Read SEC document |
| May 03, 2023 Filed May 9, 2023 01:44 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 58,800 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001437749-23-013121 · rdgdoc.xml · derivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,800 Underlying: Common Stock · 58,800 shares Expires 2033-05-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: 33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. Read SEC document |
| November 30, 2021 Filed Dec 28, 2021 21:25 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 502,008 | $0.02 | $12,500.00 |
DisclosureSEC source: 0001612084-21-000003 · primary_doc.xml · nonDerivative · entry 3 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500,984 F1 · shares: Independent Director Compensation Read SEC document |
| August 31, 2021 Filed Dec 28, 2021 21:25 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 592,417 | $0.02 | $12,500.00 |
DisclosureSEC source: 0001612084-21-000003 · primary_doc.xml · nonDerivative · entry 2 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,998,976 F1 · shares: Independent Director Compensation Read SEC document |
| May 31, 2021 Filed Dec 28, 2021 21:25 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 396,825 | $0.03 | $12,499.99 |
DisclosureSEC source: 0001612084-21-000003 · primary_doc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,406,559 F1 · shares: Independent Director Compensation Read SEC document |
| February 28, 2021 Filed Apr 19, 2021 20:49 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 459,559 | $0.03 | $12,500.00 |
DisclosureSEC source: 0001612084-21-000001 · primary_doc.xml · nonDerivative · entry 2 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,009,734 F1 · shares: Independent Director Compensation Read SEC document |
| November 30, 2020 Filed Apr 19, 2021 20:49 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 1,420,455 | $0.01 | $12,500.00 |
DisclosureSEC source: 0001612084-21-000001 · primary_doc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,550,175 F1 · shares: Independent Director Compensation Read SEC document |
| August 31, 2020 Filed Oct 14, 2020 22:10 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 675,676 | $0.02 | $12,500.01 |
DisclosureSEC source: 0001612084-20-000001 · primary_doc.xml · nonDerivative · entry 5 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,129,720 F1 · shares: Independent Director Compensation Read SEC document |
| May 31, 2020 Filed Oct 14, 2020 22:10 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 2,604,167 | $0.00 | $12,500.00 |
DisclosureSEC source: 0001612084-20-000001 · primary_doc.xml · nonDerivative · entry 4 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,454,044 F1 · shares: Independent Director Compensation Read SEC document |
| February 29, 2020 Filed Oct 14, 2020 22:10 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 2,083,333 | $0.01 | $12,500.00 |
DisclosureSEC source: 0001612084-20-000001 · primary_doc.xml · nonDerivative · entry 3 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849,877 F1 · shares: Independent Director Compensation Read SEC document |
| May 31, 2019 Filed Jul 9, 2019 16:46 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 245,098 | $0.05 | $12,500.00 |
DisclosureSEC source: 0001612084-19-000001 · primary_doc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,098 F1 · shares: 1. Restricted stock, to be vested, common shares with a value of $12,500 on each of May 31, 2019; August 31, 2019; November 30, 2019; and February 29, 2020, pursuant to an Independent Director Agreement dated March 1, 2019. Read SEC document |
| November 30, 2018 Filed Oct 14, 2020 22:10 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 781,250 | $0.02 | $12,500.00 |
DisclosureSEC source: 0001612084-20-000001 · primary_doc.xml · nonDerivative · entry 2 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766,544 F1 · shares: Independent Director Compensation Read SEC document |
| August 31, 2018 Filed Oct 14, 2020 22:10 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 490,196 | $0.03 | $12,500.00 |
DisclosureSEC source: 0001612084-20-000001 · primary_doc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,294 F1 · shares: Independent Director Compensation Read SEC document |
| March 01, 2018 Filed Mar 20, 2018 21:01 UTC | FISION Corp FSSN · Entity 131111 | GrantCommon Stock | 250,000 | $0.20 | $50,000.00 |
DisclosureSEC source: 0001612084-18-000002 · primary_doc.xml · nonDerivative · entry 1 Bode John B · CIK 0001612084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · shares: Restricted stock, to be vested quarterly as follows: 62,500 shares on May 31, 2018; 62,500 shares on August 31, 2018; 62,500 shares on November 30, 2018; and 62,500 shares on February 28, 2019, pursuant to an Independent Director Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.